Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caniplas is a hyperimmunized, fresh frozen, single-donor, cell-free canine plasma product used in veterinary medicine to supplement clotting factors and immunoglobulins in dogs. It is produced from carefully screened donor dogs that are hyperimmunized to achieve high gamma globulin (IgG) and specific antibody titers, particularly against pathogens such as canine parvovirus and endotoxin, thereby providing passive immunity and anti–TNFα activity that can modulate inflammatory cascades. Caniplas is indicated as a plasma transfusion product in conditions where administration of fresh frozen plasma is appropriate, including acute pancreatitis, parvoviral and other severe diarrheic diseases, coagulopathies, occult bleeding, von Willebrand disease, severe tissue trauma, thrombocytopenia, and hypoproteinemia, with reported benefits in shortening treatment periods, improving survival, and reducing hospitalization and concurrent drug use.[1][3][4][7][8][9][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Caniplas.